Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Pagano MB, Allen ES, Chou ST, Dunbar NM, Gniadek T, Goel R, et al. Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee. Transfusion. 2020;60(7):1614-1623.

Siddiqui MT. Serous cavity fluids: Momentum, molecules, markers… and more! Cancer Cytopathol. 2020;128(6):381-383.

Magro CM, J Mulvey J, Laurence J, Seshan S, A Crowson N, Dannenberg AJ, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020;106:106-116.

Althoff MJ, Nayak RC, Hegde S, Wellendorf AM, Bohan B, Filippi M-, et al. Yap1-Scribble polarization is required for hematopoietic stem cell division and fate. Blood. 2020;136(16):1824-1836.

Magro C, Schwartz Z, Saab J, Hedayat A. Enhanced cutaneous Rock2 expression as a marker of Rho Kinase pathway activation in autoimmune disease and Kohlemeier-Degos disease. Ann Diagn Pathol. 2020;44:151414.

Schwartz Z, Bender A, Magro CM. Solitary congenital Langerhans cell histiocytoma: A pattern of benign, spontaneous regression in patients with single lesion disease. Pediatr Dermatol. 2020;37(6):1009-1013.

Georgesen C, Magro C. Lymphomatoid papulosis in children and adolescents: A clinical and histopathologic retrospective cohort. Ann Diagn Pathol. 2020;46:151486.

Turner SD, Inghirami G, Miranda RN, Kadin ME. Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Am J Pathol. 2020;190(1):2-10.

Zhou P, Yan F. CRL4 Ubiquitin Pathway and DNA Damage Response. Adv Exp Med Biol. 2020;1217:225-239.

Wang Q, Jia S, Wang D, Chen X, Kalvakolanu DV, Zheng H, et al. A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis. Mol Cancer Ther. 2020;19(12):2542-2553.